The German drugmaker is selling the brands, which had revenues exceeding $328 million in 2017, so it can concentrate on integrating MonsantoOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.